Rituximab biosimilar (Sandoz)

利妥昔单抗生物类似药（山德士）

Report date: 2026/05/26 20:00:28

Base Information

Drug NameRituximab biosimilar (Sandoz)
Drug Alias Name利妥昔单抗生物仿制药（山德士）RiximyoRixathonGP-2013
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsPemphigusMicroscopic PolyangiitisGranulomatosis with Polyangiitis +[8] 
Global Approved IndicationsPemphigusMicroscopic PolyangiitisGranulomatosis with Polyangiitis +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2017/06/15
Country/TerritoryBelgiumBulgariaUnited States +[31] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSandoz
China Registration ClassN/A

Develop Information

Active CompaniesClariant Produkte (Schweiz) AgSandoz Gmbh
Inactive CompaniesSandozHexal AgNovartis Pharma Ag
Active IndicationsPemphigusMicroscopic PolyangiitisGranulomatosis with Polyangiitis +[6] 
Inactive IndicationsLymphoma, FollicularLymphoma, B-Cell

Other Information

ATC CodeL01XC02
Related LinksN/A